Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-04-15 pm EDT 5-day change 1st Jan Change
231.2 USD -1.31% Intraday chart for Iqvia Holdings Inc. -4.28% -0.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US MT
Iqvia, Salesforce Collaborate to Accelerate Life Sciences Cloud Development MT
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud CI
Acrux, TruPharma Launch Dapsone 5% Gel in US MT
Dr. Reddy's Laboratories Signs Deal to Distribute Sanofi's Vaccine Brands MT
Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time RE
Transcript : IQVIA Holdings Inc. - Special Call
Transcript : IQVIA Holdings Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM
Iqvia Holdings Insider Sold Shares Worth $3,494,034, According to a Recent SEC Filing MT
Iqvia Holdings Insider Sold Shares Worth $7,936,193, According to a Recent SEC Filing MT
Iqvia Holdings Insider Sold Shares Worth $2,153,176, According to a Recent SEC Filing MT
Transcript : IQVIA Holdings Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 09:30 AM
Truist Securities Raises IQVIA Holdings Price Target to $297 From $286, Maintains Buy Rating MT
Leerink Partners Starts Coverage on IQVIA With Outperform Rating, $290 Price Target MT
John Chevedden Submits a Shareholder Proposal to IQVIA Holdings CI
Nvidia and the moon Our Logo
ANALYST RECOMMENDATIONS : Block, Quanta Services, Nvidia, Home Depot, Nutrien... Our Logo
Iqvia Holdings Insider Sold Shares Worth $3,247,165, According to a Recent SEC Filing MT
Deutsche Bank Raises IQVIA Holdings Price Target to $280 From $245, Maintains Buy Rating MT
North American Morning Briefing : S&P 500 Seen -2- DJ
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
UBS Adjusts IQVIA Holdings Price Target to $300 From $240, Maintains Buy Rating MT
Barclays Adjusts Price Target on IQVIA to $265 From $260, Maintains Overweight Rating MT
Baird Adjusts Price Target on IQVIA Holdings to $251 From $226, Maintains Neutral Rating MT
Guggenheim Downgrades IQVIA Holdings to Neutral From Buy MT
Chart Iqvia Holdings Inc.
More charts
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
231.2 USD
Average target price
275.4 USD
Spread / Average Target
+19.13%
Consensus
  1. Stock Market
  2. Equities
  3. IQV Stock
  4. News Iqvia Holdings Inc.
  5. BTIG Initiates IQVIA Holdings With Buy Rating, $285 Price Target